Obesity and diabetes drug R&D partnerships struck in 2025 represented $20.2 billion in total deal value, a new record high, according to a new report from J.P. Morgan. While IPO activity and venture investment trended downward, M&A activity was significantly higher.
The post J.P. Morgan Report: Obesity & Diabetes Dealmaking Set a New Record in 2025 appeared first on MedCity News.
